Direct, Differential Effects of Tamoxifen, 4-Hydroxytamoxifen, and Raloxifene on Cardiac Myocyte Contractility and Calcium Handling

PLoS ONE

Volumn 8, Issue 10, 2013, Pages

  Asp, Michelle L ^a   Martindale, Joshua J ^a   Metzger, Joseph M ^a  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AFIMOXIFENE; CALCIUM ION; CYCLIC AMP DEPENDENT PROTEIN KINASE; ESTROGEN RECEPTOR; RALOXIFENE; TAMOXIFEN; TROPONIN I;

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; BINDING AFFINITY; CARDIOMYOPATHY; CARDIOVASCULAR RESPONSE; CELL GROWTH; CONTROLLED STUDY; DRUG EFFICACY; DRUG RECEPTOR BINDING; GROWTH INHIBITION; HEART MUSCLE CELL; HEART MUSCLE CONTRACTILITY; HEART MUSCLE RELAXATION; MOUSE; NONHUMAN; PATHOGENESIS; PROTEIN DEPHOSPHORYLATION; PROTEIN PHOSPHORYLATION; RAT; RELAXATION TIME; SARCOMERE LENGTH;

ANIMALS; BIOMECHANICAL PHENOMENA; CALCIUM; FEMALE; MICE; MUSCLE CONTRACTION; MYOCYTES, CARDIAC; RALOXIFENE; RATS; RATS, SPRAGUE-DAWLEY; SARCOMERES; TAMOXIFEN;

EID: 84886266161     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0078768     Document Type: Article

References (43)

1. Umar A, Dunn BK, Greenwald P, (2012) Future directions in cancer prevention. Nat Rev Cancer 12: 835-848. doi:10.1038/nrc3397. PubMed: 23151603.
2. Michalski A, Bouffet E, Taylor RE, Hargrave D, Walker D, et al. (2010) The addition of high-dose tamoxifen to standard radiotherapy does not improve the survival of patients with diffuse intrinsic pontine glioma. J Neuro Oncol 100: 81-88. doi:10.1007/s11060-010-0141-9.
3. Tang P, Roldan G, Brasher PM, Fulton D, Roa W, et al. (2006) A phase II study of carboplatin and chronic high-dose tamoxifen in patients with recurrent malignant glioma. J Neuro Oncol 78: 311-316. doi:10.1007/s11060-005-9104-y.
4. Pollack IF, DaRosso RC, Robertson PL, Jakacki RL, Mirro JR Jr., et al. (1997) A phase I study of high-dose tamoxifen for the treatment of refractory malignant gliomas of childhood. Clin Cancer Res 3: 1109-1115. PubMed: 9815790.
5. Patel S, DiBiase S, Meisenberg B, Flannery T, Patel A, et al. (2012) Phase I clinical trial assessing temozolomide and tamoxifen with concomitant radiotherapy for treatment of high-grade glioma. Int J Radiat Oncol Biol Phys 82: 739-742. PubMed: 21353747.
6. Stuart NS, Philip P, Harris AL, Tonkin K, Houlbrook S, et al. (1992) High-dose tamoxifen as an enhancer of etoposide cytotoxicity. Clinical effects and in vitro assessment in p-glycoprotein expressing cell lines. Br J Cancer 66: 833-839. doi:10.1038/bjc.1992.369. PubMed: 1358168.
7. Trump DL, Smith DC, Ellis PG, Rogers MP, Schold SC, et al. (1992) High-dose oral tamoxifen, a potential multidrug-resistance-reversal agent: phase I trial in combination with vinblastine. J Natl Cancer Inst 84: 1811-1816. doi:10.1093/jnci/84.23.1811. PubMed: 1359155.
8. O'Brian CA, Liskamp RM, Solomon DH, Weinstein IB, (1985) Inhibition of protein kinase C by tamoxifen. Cancer Res 45: 2462-2465. PubMed: 3157445.
9. Berman E, Adams M, Duigou-Osterndorf R, Godfrey L, Clarkson B, et al. (1991) Effect of tamoxifen on cell lines displaying the multidrug-resistant phenotype. Blood 77: 818-825. PubMed: 1993221.
10. Slovacek L, Ansorgova V, Macingova Z, Haman L, Petera J, (2008) Tamoxifen-induced QT interval prolongation. J Clin Pharm Ther 33: 453-455. doi:10.1111/j.1365-2710.2008.00928.x. PubMed: 18613864.
11. Beca S, Pavlov E, Kargacin ME, Aschar-Sobbi R, French RJ, et al. (2008) Inhibition of a cardiac sarcoplasmic reticulum chloride channel by tamoxifen. Pflugers Arch 457: 121-135. doi:10.1007/s00424-008-0510-9. PubMed: 18458943.
12. Ponce-Balbuena D, López-Izquierdo A, Ferrer T, Rodríguez-Menchaca AA, Aréchiga-Figueroa IA, et al. (2009) Tamoxifen inhibits inward rectifier K+ 2.x family of inward rectifier channels by interfering with phosphatidylinositol 4,5-bisphosphate-channel interactions. J Pharmacol Exp Ther 331: 563-573. doi:10.1124/jpet.109.156075. PubMed: 19654266.
13. Ponce-Balbuena D, Moreno-Galindo EG, López-Izquierdo A, Ferrer T, Sánchez-Chapula JA, (2010) Tamoxifen inhibits cardiac ATP-sensitive and acetylcholine-activated K+ currents in part by interfering with phosphatidylinositol 4,5-bisphosphate-channel interaction. J Pharmacol Sci 113: 66-75. doi:10.1254/jphs.10024FP. PubMed: 20472984.
14. Vasioukhin V, Degenstein L, Wise B, Fuchs E, (1999) The magical touch: genome targeting in epidermal stem cells induced by tamoxifen application to mouse skin. Proc Natl Acad Sci U S A 96: 8551-8556. doi:10.1073/pnas.96.15.8551. PubMed: 10411913.
15. McCarthy JJ, Srikuea R, Kirby TJ, Peterson CA, Esser KA, (2012) Inducible Cre transgenic mouse strain for skeletal muscle-specific gene targeting. Skelet Muscle 2: 8. doi:10.1186/2044-5040-2-8. PubMed: 22564549.
16. Hirrlinger PG, Scheller A, Braun C, Hirrlinger J, Kirchhoff F, (2006) Temporal control of gene recombination in astrocytes by transgenic expression of the tamoxifen-inducible DNA recombinase variant CreERT2. Glia 54: 11-20. doi:10.1002/glia.20342. PubMed: 16575885.
17. Gómez-Casati ME, Murtie J, Taylor B, Corfas G, (2010) Cell-specific inducible gene recombination in postnatal inner ear supporting cells and glia. J Assoc Res Otolaryngol 11: 19-26. doi:10.1007/s10162-009-0191-x. PubMed: 19820996.
18. Sohal DS, Nghiem M, Crackower MA, Witt SA, Kimball TR, et al. (2001) Temporally regulated and tissue-specific gene manipulations in the adult and embryonic heart using a tamoxifen-inducible Cre protein. Circ Res 89: 20-25. doi:10.1161/hh1301.092687. PubMed: 11440973.
19. Littlewood TD, Hancock DC, Danielian PS, Parker MG, Evan GI, (1995) A modified oestrogen receptor ligand-binding domain as an improved switch for the regulation of heterologous proteins. Nucleic Acids Res 23: 1686-1690. doi:10.1093/nar/23.10.1686. PubMed: 7784172.
20. Zhang Y, Riesterer C, Ayrall AM, Sablitzky F, Littlewood TD, et al. (1996) Inducible site-directed recombination in mouse embryonic stem cells. Nucleic Acids Res 24: 543-548. doi:10.1093/nar/24.4.543. PubMed: 8604292.
21. Danielian PS, White R, Hoare SA, Fawell SE, Parker MG, (1993) Identification of residues in the estrogen receptor that confer differential sensitivity to estrogen and hydroxytamoxifen. Mol Endocrinol 7: 232-240. doi:10.1210/me.7.2.232. PubMed: 8469236.
22. Pratt WB, (1990) Interaction of hsp90 with steroid receptors: organizing some diverse observations and presenting the newest concepts. Mol Cell Endocrinol 74: C69-C76. doi:10.1016/0303-7207(90)90198-H. PubMed: 2178103.
23. Davis J, Maillet M, Miano JM, Molkentin JD, (2012) Lost in transgenesis: a user's guide for genetically manipulating the mouse in cardiac research. Circ Res 111: 761-777. doi:10.1161/CIRCRESAHA.111.262717. PubMed: 22935533.
24. Buerger A, Rozhitskaya O, Sherwood MC, Dorfman AL, Bisping E, et al. (2006) Dilated cardiomyopathy resulting from high-level myocardial expression of Cre-recombinase. J Card Fail 12: 392-398. doi:10.1016/j.cardfail.2006.03.002. PubMed: 16762803.
25. Koitabashi N, Bedja D, Zaiman AL, Pinto YM, Zhang M, et al. (2009) Avoidance of transient cardiomyopathy in cardiomyocyte-targeted tamoxifen-induced MerCreMer gene deletion models. Circ Res 105: 12-15. doi:10.1161/CIRCRESAHA.109.198416. PubMed: 19520971.
26. Hougen K, Aronsen JM, Stokke MK, Enger U, Nygard S, et al. (2010) Cre-loxP DNA recombination is possible with only minimal unspecific transcriptional changes and without cardiomyopathy in Tg(alphaMHC-MerCreMer) mice. Am J Physiol Heart Circ Physiol 299: H1671-H1678. doi:10.1152/ajpheart.01155.2009. PubMed: 20802136.
27. Kravtsov GM, Kam KW, Liu J, Wu S, Wong TM, (2007) Altered Ca(2+) handling by ryanodine receptor and Na(+)-Ca(2+) exchange in the heart from ovariectomized rats: role of protein kinase A. Am J Physiol Cell Physiol 292: C1625-C1635. PubMed: 17166940.
28. Filice E, Angelone T, De Francesco EM, Pellegrino D, Maggiolini M, et al. (2011) Crucial role of phospholamban phosphorylation and S-nitrosylation in the negative lusitropism induced by 17β-estradiol in the male rat heart. Cell Physiol Biochem 28: 41-52. doi:10.1159/000331712. PubMed: 21865847.
29. Kulpa J, Chinnappareddy N, Pyle WG, (2012) Rapid changes in cardiac myofilament function following the acute activation of estrogen receptor-alpha. PLOS ONE 7: e41076. doi:10.1371/journal.pone.0041076. PubMed: 22859967.
30. Wang W, Barnabei MS, Asp ML, Heinis FI, Arden E, et al. (2013) Noncanonical EF-hand motif strategically delays Ca2+ buffering to enhance cardiac performance. Nat Med 19: 305-312. doi:10.1038/nm.3079. PubMed: 23396207.
31. Sideras K, Ingle JN, Ames MM, Loprinzi CL, Mrazek DP, et al. (2010) Coprescription of tamoxifen and medications that inhibit CYP2D6. J Clin Oncol 28: 2768-2776. doi:10.1200/JCO.2009.23.8931. PubMed: 20439629.
32. Katzenellenbogen BS, Norman MJ, Eckert RL, Peltz SW, Mangel WF, (1984) Bioactivities, estrogen receptor interactions, and plasminogen activator-inducing activities of tamoxifen and hydroxy-tamoxifen isomers in MCF-7 human breast cancer cells. Cancer Res 44: 112-119. PubMed: 6537799.
33. Filice E, Recchia AG, Pellegrino D, Angelone T, Maggiolini M, et al. (2009) A new membrane G protein-coupled receptor (GPR30) is involved in the cardiac effects of 17beta-estradiol in the male rat. J Physiol Pharmacol 60: 3-10. PubMed: 20065491.
34. Duan J, Esberg LB, Dai S, Aberle NS, Lopez FL, et al. (2004) Comparison of cardiac contractile and intracellular Ca2+ response between estrogen and phytoestrogen alpha-zearalanol in ventricular myocytes. Endocrine 24: 33-38. doi:10.1385/ENDO:24:1:033. PubMed: 15249701.
35. He J, Kargacin ME, Kargacin GJ, Ward CA, (2003) Tamoxifen inhibits Na+ and K+ currents in rat ventricular myocytes. Am J Physiol Heart Circ Physiol 285: H661-H668. PubMed: 12702490.
36. Song J, Standley PR, Zhang F, Joshi D, Gappy S, et al. (1996) Tamoxifen (estrogen antagonist) inhibits voltage-gated calcium current and contractility in vascular smooth muscle from rats. J Pharmacol Exp Ther 277: 1444-1453. PubMed: 8667209.
37. Ullrich ND, Krust A, Collins P, MacLeod KT, (2008) Genomic deletion of estrogen receptors ERalpha and ERbeta does not alter estrogen-mediated inhibition of Ca2+ influx and contraction in murine cardiomyocytes. Am J Physiol Heart Circ Physiol 294: H2421-H2427. doi:10.1152/ajpheart.01225.2007. PubMed: 18441199.
38. Kargacin ME, Ali Z, Ward CA, Pollock NS, Kargacin GJ, (2000) Tamoxifen inhibits Ca2+ uptake by the cardiac sarcoplasmic reticulum. Pflugers Arch 440: 573-579. doi:10.1007/s004240050008. PubMed: 10958341.
39. Xie L, Wang J, Bourne PE, (2007) In silico elucidation of the molecular mechanism defining the adverse effect of selective estrogen receptor modulators. PLOS Comput Biol 3: e217. doi:10.1371/journal.pcbi.0030217. PubMed: 18052534.
40. Liew R, Stagg MA, MacLeod KT, Collins P, (2004) Raloxifene acutely suppresses ventricular myocyte contractility through inhibition of the L-type calcium current. Br J Pharmacol 142: 89-96. doi:10.1038/sj.bjp.0705736. PubMed: 15023859.
41. Lewartowski B, Zdanowski K, (1990) Net Ca2+ influx and sarcoplasmic reticulum Ca2+ uptake in resting single myocytes of the rat heart: comparison with guinea-pig. J Mol Cell Cardiol 22: 1221-1229. doi:10.1016/0022-2828(90)90059-B. PubMed: 2283683.
42. Furlanut M, Franceschi L, Pasqual E, Bacchetti S, Poz D, et al. (2007) Tamoxifen and its main metabolites serum and tissue concentrations in breast cancer women. Ther Drug Monit 29: 349-352. doi:10.1097/FTD.0b013e318067ded7. PubMed: 17529893.
43. Kisanga ER, Gjerde J, Schjøtt J, Mellgren G, Lien EA, (2003) Tamoxifen administration and metabolism in nude mice and nude rats. J Steroid Biochem Mol Biol 84: 361-367. doi:10.1016/S0960-0760(03)00051-7. PubMed: 12711024.